Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Hepatic Stress Response in HCV Infection Promotes STAT3-Mediated Inhibition of HNF4A-miR-122 Feedback Loop in Liver Fibrosis and Cancer Progression.

Aydin Y, Kurt R, Song K, Lin D, Osman H, Youngquist B, Scott JW, Shores NJ, Thevenot P, Cohen A, Dash S.

Cancers (Basel). 2019 Sep 20;11(10). pii: E1407. doi: 10.3390/cancers11101407.

2.

Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression.

Ferraris P, Chandra PK, Panigrahi R, Aboulnasr F, Chava S, Kurt R, Pawlotsky JM, Wilkens L, Osterlund P, Hartmann R, Balart LA, Wu T, Dash S.

Am J Pathol. 2016 Apr;186(4):938-51. doi: 10.1016/j.ajpath.2015.11.027. Epub 2016 Feb 16.

3.

IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.

Aboulnasr F, Hazari S, Nayak S, Chandra PK, Panigrahi R, Ferraris P, Chava S, Kurt R, Song K, Dash A, Balart LA, Garry RF, Wu T, Dash S.

PLoS One. 2015 Dec 11;10(12):e0141655. doi: 10.1371/journal.pone.0141655. eCollection 2015.

4.

Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture.

Kurt R, Chandra PK, Aboulnasr F, Panigrahi R, Ferraris P, Aydin Y, Reiss K, Wu T, Balart LA, Dash S.

PLoS One. 2015 May 11;10(5):e0125962. doi: 10.1371/journal.pone.0125962. eCollection 2015.

5.

Persistent hepatitis C virus infection impairs ribavirin antiviral activity through clathrin-mediated trafficking of equilibrative nucleoside transporter 1.

Panigrahi R, Chandra PK, Ferraris P, Kurt R, Song K, Garry RF, Reiss K, Coe IR, Furihata T, Balart LA, Wu T, Dash S.

J Virol. 2015 Jan;89(1):626-42. doi: 10.1128/JVI.02492-14. Epub 2014 Oct 22.

6.

Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis.

Chandra PK, Gunduz F, Hazari S, Kurt R, Panigrahi R, Poat B, Bruce D, Cohen AJ, Bohorquez HE, Carmody I, Loss G, Balart LA, Wu T, Dash S.

PLoS One. 2014 Sep 29;9(9):e108616. doi: 10.1371/journal.pone.0108616. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e114456. Behorquez, Humberto E [corrected to Bohorquez, Humberto E].

7.

Does Illness Perception Predict Posttraumatic Stress Disorder in Patients with Myocardial Infarction?

Oflaz S, Yüksel Ş, Şen F, Özdemiroğlu F, Kurt R, Oflaz H, Kaşikcioğlu E.

Noro Psikiyatr Ars. 2014 Jun;51(2):103-109. doi: 10.4274/npa.y6394. Epub 2014 Jun 1.

8.

Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation.

Panigrahi R, Hazari S, Chandra S, Chandra PK, Datta S, Kurt R, Cameron CE, Huang Z, Zhang H, Garry RF, Balart LA, Dash S.

PLoS One. 2013 Aug 23;8(8):e72791. doi: 10.1371/journal.pone.0072791. eCollection 2013.

9.

Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back.

Yilmaz Y, Colak Y, Kurt R, Senates E, Eren F.

Tumori. 2013 Jan-Feb;99(1):10-6. doi: 10.1700/1248.13781. Review.

PMID:
23548993
10.

Skull metastasis from hepatocellular carcinoma with hepatitis C.

Ermis F, Dursun M, Kurt R, Akyuz F.

Ann Saudi Med. 2012 May-Jun;32(3):321-2. doi: 10.5144/0256-4947.2012.321. No abstract available.

11.

Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease.

Eren F, Kurt R, Ermis F, Atug O, Imeryuz N, Yilmaz Y.

Clin Biochem. 2012 Jun;45(9):655-8. doi: 10.1016/j.clinbiochem.2012.03.019. Epub 2012 Mar 19.

PMID:
22465275
12.

Unconjugated hyperbilirubinemia and liver histology in patients with non-alcoholic fatty liver disease.

Kurt R, Yilmaz Y.

Clin Biochem. 2012 Apr;45(6):515. doi: 10.1016/j.clinbiochem.2012.01.030. Epub 2012 Feb 9. No abstract available.

PMID:
22342919
13.

Is M65 really better than M30 as a biomarker of hepatic fibrosis?

Yilmaz Y, Kurt R.

Hepatology. 2012 Feb;55(2):654; author reply 654-5. doi: 10.1002/hep.25520. No abstract available.

PMID:
22161311
15.

Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease.

Yilmaz Y, Eren F, Yonal O, Polat Z, Bacha M, Kurt R, Ozturk O, Avsar E.

Dis Markers. 2011;31(4):205-10. doi: 10.3233/DMA-2011-0815.

16.

Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis.

Yilmaz Y, Eren F, Ayyildiz T, Colak Y, Kurt R, Senates E, Tuncer I, Dolar E, Imeryuz N.

Clin Chim Acta. 2011 Nov 20;412(23-24):2296-9. doi: 10.1016/j.cca.2011.08.025. Epub 2011 Aug 24.

PMID:
21888902
17.

Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer.

Ermis F, Akyuz F, Uyanikoglu A, Kurt R, Pinarbasi B, Nazik H, Kaymakoglu S, Mungan Z.

South Med J. 2011 Aug;104(8):579-83. doi: 10.1097/SMJ.0b013e3182249be0.

PMID:
21886067
18.

Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration.

Yilmaz Y, Kurt R, Eren F, Imeryuz N.

Scand J Clin Lab Invest. 2011 Dec;71(8):631-6. doi: 10.3109/00365513.2011.604427. Epub 2011 Aug 22.

PMID:
21859358
19.

Multimarker strategies for detecting NASH and NASH-related fibrosis: promises and caveats.

Yilmaz Y, Kurt R, Eren F.

Obes Surg. 2011 Aug;21(8):1316-7; author reply 1318. doi: 10.1007/s11695-011-0464-4. No abstract available.

PMID:
21667321
20.

Serum galectin-3 levels in patients with nonalcoholic fatty liver disease.

Yilmaz Y, Eren F, Kurt R, Yonal O, Polat Z, Senates E, Bacha M, Imeryuz N.

Clin Biochem. 2011 Aug;44(12):955-8. doi: 10.1016/j.clinbiochem.2011.05.015. Epub 2011 May 24.

PMID:
21635880

Supplemental Content

Loading ...
Support Center